IONIS-FB-LRx

complement factor B antisense inhibitor · Ionis Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IONIS-FB-LRx, covering 2025-01-23 to 2025-03-07. Get the full timeline:

Most recent: Clinical Trial Update: GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) [Phase 2]

See pricing